CSPC Pharmaceutical Group Limited 1093
HKEX · Hong Kong SAR China · Health Technology
HKD 10.07+0.60 (+6.28%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
Non-small cell lung cancer is increasingly evolving into a biomarker-driven market, with EGFR-mutated disease emerging as one of the most commercially significant segments. The space is dominated by blockbuster EGFR-targeted therapies such as TAGRISSO, which now generates nearly USD 6 billion annually, reinforcing the importance of precision medicine in NSCLC management.
CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval in China to start clinical trials for its new antibody drug conjugate SYS6051. The therapy targets advanced solid tumors and has been cleared as a Class 1 biological drug candidate. The approval allows the company to begin clinical evaluation of SYS6051 across a broad range of advanced cancers. CSPC Pharmaceutical Group, a major player in China's pharmaceutical sector, has been building out its oncology pipeline...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.